September 8, 2017
Japanese dermatology powerhouse Maruho plans to kick off a PIII trial in Japan for nemolizumab, an anti-IL-31 receptor A humanized monoclonal antibody originated by Chugai Pharmaceutical, for the treatment of atopic dermatitis, the company told Jiho on September 7. The...read more